Edition:
United Kingdom

Tecan Group AG (TECN.S)

TECN.S on Swiss Exchange

203.40CHF
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
CHF203.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,473
52-wk High
CHF217.80
52-wk Low
CHF148.80

Summary

Name Age Since Current Position

Rolf Classon

72 2009 Non-Executive Chairman of the Board

David Martyr

60 2012 Chief Executive Officer, Member of the Management Board

Heinrich Fischer

67 2007 Non-Executive Vice Chairman of the Board

Rudolf Eugster

52 2002 Chief Financial Officer, Member of the Management Board

Ulrich Kanter

54 2014 Executive Vice President, Head of the Division Development and Operations, Member of the Management Board

Andreas Wilhelm

48 2012 Executive Vice President, General Counsel and Secretary, Member of the Management Board

Markus Schmid

49 2011 Executive Vice President, Head of Corporate Human Resources & Internal Communications, Member of the Management Board

Klaus Lun

45 2017 Executive Vice President Head of the Life Sciences Business division & Head of Corporate Development, Member of the Management Board

Achim von Leoprechting

49 2013 Executive Vice President, Head of the Partnering Business division, Member of the Management Board

Martin Braendle

2017 Vice President, Communications & Investor Relations

Oliver Fetzer

52 2011 Non-Executive Director

Lars Holmqvist

58 2015 Non-Executive Director

Karen Huebscher

54 2012 Non-Executive Director

Christa Kreuzburg

58 2013 Non-Executive Director

Gerard Vaillant

75 2012 Non-Executive Director

Biographies

Name Description

Rolf Classon

Mr. Rolf A. Classon was Non-Executive Chairman of the Board at Tecan Group Ltd. from April 22, 2009 to April 17, 2018. He was also Chairman of the Nomination and Governance Committee at the Company. He sits on the Board of various United States and European companies in the life science sector. He holds a degree in chemical engineering from Goteborgs Universitaet. Mr. Classon's professional background include the positions of Director, Organization Development at Pharmacia AB (1969-1974), Consultant at Asbjorn Habberstad AB (1974-1978), President of Pharmacia AB Hospital Products Division (1979-1984), President of Pharmacia Development Company, Inc (1984-1990), President and COO at Pharmacia Biosystems AB (1990-1991), Executive Vice President of Bayer Diagnostics (1991-1995), President of Bayer Diagnostics (1995-2002), CEO and Chairman of the Executive Committee at Bayer HealtCare (2002-2004) and the recent position of interim President and CEO of Hillenbrand Industries (2005-2006). Currently, he serves as Non-executive Chairman at Hill- Rom Holdings, as well as Member of the Board at Fresenius Medical Care AG and Catalent, Inc.

David Martyr

Dr. David R. Martyr is Chief Executive Officer and Member of the Management Board of Tecan Group Ltd. since October 2012. From 1989 to 1998 he held variety of management and sales related positions at Lumonics Inc., including Managing Director Europe; 1998 to 2007 various senior management and professional positions at Leica Microsystems, including Executive Vice President Worldwide Sales and Marketing and Managing Director Europe; 2009 to 2011 Group Executive and Vice President of Danaher Corporation. He holds B.Sc. and doctorate in Engineering from University of Newcastle.

Heinrich Fischer

Mr. Heinrich Fischer is Non-Executive Vice Chairman of the Board of Tecan Group Ltd. since December 31, 2007. He is also Chairman of the Audit Committee and Member of the Nomination and Governance Committee at the Company. He was appointed to the Board on April 19, 2007. He holds Master of Applied Physics and Electrical Engineering from Eidgenoessische Technische Hochschule Zuerich (ETH, Swiss Federal Institute of Technology) and a Master of Business Administration from Universitaet Zuerich. He spent four years in Research & Development in electronics (ETH Zurich, IBM). From 1980 to 1990, he was Director of Staff Technology and Executive Vice President at Balzers Division of Oerlikon-Buehrle Group. From 1991 to 1996, he was Executive Vice President, Corporate Development at Oerlikon-Buehrle Group. From 1994 to 2005, he was Cofounder and Chairman of ISE (Integrated System Engineering). From 1996 to 2007, he was a Delegated member of the board and Chief Executive Saurer Group. He is also a Member of the Board of Sensirion Holding AG, CAMOX Fund, Hilti AG and SWM Inc. and Chairman of the Board of Orell Fuessli Holding AG.

Rudolf Eugster

Dr. Rudolf Eugster is Chief Financial Officer and Member of the Management Board at Tecan Group Ltd. since December 1, 2002. He was involved in strategic planning and controlling at Novartis from 1993 until 1994 and held several positions at Von Roll between 1994 and 2002, the last of which was Chief Financial Officer of Isola Composites, a joint venture between Von Roll and Isola AG. He has a degree in Chemistry, a Doctorate in Philosophy in Technical Science and a postgraduate degree in Business Administration, all from Eidgenoessische Technische Hochschule Zuerich (Swiss Federal Institute of Technology).

Ulrich Kanter

Mr. Ulrich Kanter is Executive Vice President, Head of the Division Development and Operations and Member of the Management Board at Tecan Group Ltd. since July 2014. From 1995 to 2000 he was Vice President, Operations and Global Supply Chain Manager at AVL Medizintechnik (acquired by Roche Diagnostics in 2000); and from 2000 to 2014 he held diverse positions with increasing management responsibility at Roche Diagnostics, most recently as General Manager and Head of Research & Development in Graz, Austria. He is Mechanical Engineer (Berufsakademie Mannheim, Germany) and holds a Diploma in Business Administration (Verwaltungs- und Wirtschaftsakademie at the J.W. Goethe Universitaet Frankfurt am Main).

Andreas Wilhelm

Mr. Andreas Wilhelm is Executive Vice President, General Counsel and Secretary and Member of the Management Board of Tecan Group Ltd. since 2012. Since 2004 he has been Head Legal Affairs and Secretary of the Board of Directors of the Company. Previously, in 1993 he served as Judicial Clerk at District Court of Nidau, from 1994 to 1995 as Legal Internship at Notter&Partner in Berne, from 1996 to 1999 attorney at- law at Gruninger Hunziker Roth Rechtsanwalte in Berne, from 2000 to 2004 attorney-at-law at Bar & Karrer in Zurich. He holds a Master of Law degree from Boston University and a Law degree from University of Bern.

Markus Schmid

Mr. Markus Schmid is Executive Vice President, Head of Corporate Human Resources & Internal Communications and Member of the Management Board at Tecan Group Ltd. since 2011. Between 1990 and 1993 he acted as consultant for occupational pension funds at an insurance company. In years 1994-1998 he was teacher and instructor at various educational levels, and held various consulting positions. From 1998 to 2011 he acted as partner and operations manager at MANRES AG. He holds Masters degree in Psychology and Journalism from Freiburg University.

Klaus Lun

Dr. Klaus Lun is Executive Vice President Head of the Life Sciences Business division & Head of Corporate Development, Member of the Management Board of Tecan Group Ltd. since February 2017. He has been Executive Vice President, Head of Corporate Development and Member of the Management Board of Tecan Group Ltd. since June 2013. He held variety of positions at Amaxa GmbH, now part of the Lonza Group from 2002 to 2007, most recently as a Senior Project Manager, 2007 to 2011 Director Business Development at Leica Microsystems (Danaher Group); 2011 to 2013 Several management positions at Molecular Devices Inc. (Danaher Group), most recently as Vice President Drug Discovery and Bioresearch und Vice President Global Product Marketing. He holds a M.Sc. in Biology from the University of Tuebingen, Dr. rer. nat. in neurobiology (equiv. Ph.D.), from the University of Heidelberg and an MBA degree from the University of Mannheim.

Achim von Leoprechting

Dr. Achim von Leoprechting is Executive Vice President, Head of the Partnering Business division and Member of the Management Board at Tecan Group Ltd. since October 2013. He held different positions in product management at Packard Bioscience, today part of PerkinElmer from1999 to 2002; from 2002 to 2013 Several management positions and professional positions at PerkinElmer Inc. (NYSE:PKI), including Vice President and General Manager In Vitro Solutions and Vice President and General Manager Imaging and Detection Technologies as well as European Sales Director Molecular Medicine/Biodiscovery; most recently as Vice President and General Manager Europe, Middle East, Africa and India. He holds a Ph.D. in Biology from University of Freiburg, Germany.

Martin Braendle

Oliver Fetzer

Dr. Oliver S. Fetzer, Ph.D. is Non-Executive Director at Tecan Group Ltd. since 2011. He serves as Chairman of the Compensation Committee and Member of the Nomination and Governance Committee at the Company. He graduated from the Carnegie Mellon University with Masters of Business Administration degree and holds a Ph.D. title from the Medical University of South Carolina, the United States. From 1993 to 2002 he worked for the Boston Consulting Group. Between 2000 and 2002 he served as Managing Director and Partner for that company. From 2002 to 2007 he held various management positions, including Senior Vice President, Corporate Development and Research and Development at Cubist Pharmaceuticals. Since 2009 he has been President and Chief Executive Officer, member of the Board of Directors of Cerulean Pharma Inc. Since 2014 he has been CEO of Synthetic Genomics.

Lars Holmqvist

Mr. Lars Holmqvist is Non-Executive Director of Tecan Group Ltd. since April 2015. He is Member of the Audit Committee at the Company. From 2012 to 2014 he was President of Life Sciences and Diagnostics Group / Senior Vice President of Agilent of Agilent Technology, Inc. Prior to that, from 2009 he was President and CEO of Dako Denmark A/S. From 2004 to 2009 he held various positions, last position President and Executive Member of Applera Corp. at Applied Biostems, Inc. From 1998 till 2004 he held various positions, last position Vice President Vascular & Cardic Surgrey, Western Europe, Member of the European Management Committee and Global Vascular & Cardiac at MEDITRONICEUROPE SARL. Moreover, Mr. Holmqvist served at Boston Scientific Europe, Pharma Hospital Care, Becton Dickinson Nordic and Lederle Labs. Nordic. He is Chairman of the Board of Fastighets AB Skutviken and Member of the Board of H. Lundbeck A/S and ALK-Abello A/S, among others. He graduated from INSEAD, Fontainebleu France and holds a degree in Business Administration from Mid Sweden University, Sweden.

Karen Huebscher

Dr. Karen Huebscher is Non-Executive Director of Tecan Group Ltd. since April 2012. She is Member of the Audit Committee at the Company. Previously from 1995 to 1997 she was Research Scientist at Novartis and CIBA-Geigy, from 1997 to 2000 served as Investor Relations Manager at Novartis and from 2000 to 2005 she served as Global Head of Investor Relations. From 2006 to 2009 she was Global Head Business Development/Mergers and Acquisitions and member of the Executive Committee and Innovation Board at Novartis Vaccines & Diagnostics, USA. From 2009 to 2011 she was Head Public Health and Market Access Europe, Member of the European Commercial Operations Leadership Team and Site Head at Novartis Vaccines & Diagnostics, Basel. Since 2012 she has been Founder and Managing Director of Fibula Medical AG and since 2014 she has served as CEO of Solvias AG. She holds a Doctorate in Philosophy in Natural Sciences and a Masters degree in Animal Sciences from ETH Zurich. She also holds a Masters of Business Administration from IMD Lausanne.

Christa Kreuzburg

Dr. Christa Kreuzburg is Non-Executive Director at Tecan Group Ltd. since April 2013. She is Member of the Compensation Committee at the Company. She was from 1990 to 1994 Laboratory Head, Central Research at Bayer AG, Germany; from1994 to 1996 Departmental Head, Central Research at Bayer AG, Germany; from1997 to 1999 Strategy Consultant, Corporate Strategic Planning at Bayer AG, Germany; from 2000 to 2002 Head of Corporate Strategic Planning, in addition from 2001, heading the restructuring project of division Pharmaceuticals after the withdrawal of Lipobay at Bayer AG, Germany; from 2002 to 2005 Head of Pharma Japan (from 2004)/Europe/ MERA and member of the Pharma Management Committee at Bayer HealthCare, Germany; from 2006 to 2007 Head of Pharma Primary Care / International Operations and member of the Pharma Management Committee at Bayer HealthCare, Germany; from 2007 to 2008 Head of Bayer Schering Pharma Europe/ Canada and member of the Executive Committee. Integration of Bayer and Schering in the region at Bayer HealthCare, Germany; from 2009 to today Consulting projects for small and mid-size Healthcare companies. She is Member of the Board of Freedom Innovations LLC. She holds a Diploma and Ph.D. in Physical Chemistry from Universitaet Duisburg.

Gerard Vaillant

Mr. Gerard Vaillant was Non-Executive Director of Tecan Group Ltd. from October 2012 to April 17, 2018. Between February 2012 and October 2012, he served as Interim Chief Executive Officer at the Company. Previously he served as a Non-Executive Director of Tecan Group AG from April 28, 2004. He has held various senior management positions within Johnson & Johnson, including Vice-President, J&J International, 1987 to 1992, Worldwide President LifeScan (a J&J company), 1992 to 1995, and Company Group Chairman Diagnostics Worldwide, 1995 to 2004. Mr. Vaillant was a Member of the Medical Devices & Diagnostics Group Operating Committee of J&J until he retired in 2004. His other positions include being Chairman of the Board at Safe Orthopaedics, Patho Quest S.A.S. andSTAT-Diagnostica & Innovation S.L. He holds a Degree in Marketing from Ecole Superieure de Commerce, Paris and a Master degree in Biochemistry from the Universite Paris VI Pierre et Marie Curie.